Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, ...

Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.

Por TOM MURPHYEl mercado de tratamientos para la obesidad y la diabetes sigue siendo extremadamente activo, canalizando miles de millones de dólares en ventas para Eli Lilly y alimentando una ...

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...